vs

Side-by-side financial comparison of RE/MAX Holdings, Inc. (RMAX) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Oncology Institute, Inc. is the larger business by last-quarter revenue ($142.0M vs $71.1M, roughly 2.0× RE/MAX Holdings, Inc.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -5.3%, a 7.3% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $2.2M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs -4.7%).

RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

RMAX vs TOI — Head-to-Head

Bigger by revenue
TOI
TOI
2.0× larger
TOI
$142.0M
$71.1M
RMAX
Growing faster (revenue YoY)
TOI
TOI
+43.4% gap
TOI
41.6%
-1.8%
RMAX
Higher net margin
RMAX
RMAX
7.3% more per $
RMAX
2.0%
-5.3%
TOI
More free cash flow
RMAX
RMAX
$31.3M more FCF
RMAX
$33.5M
$2.2M
TOI
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
-4.7%
RMAX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RMAX
RMAX
TOI
TOI
Revenue
$71.1M
$142.0M
Net Profit
$1.4M
$-7.5M
Gross Margin
Operating Margin
13.1%
-4.9%
Net Margin
2.0%
-5.3%
Revenue YoY
-1.8%
41.6%
Net Profit YoY
-75.2%
43.0%
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RMAX
RMAX
TOI
TOI
Q4 25
$71.1M
$142.0M
Q3 25
$73.2M
$136.6M
Q2 25
$72.8M
$119.8M
Q1 25
$74.5M
$104.4M
Q4 24
$72.5M
$100.3M
Q3 24
$78.5M
$99.9M
Q2 24
$78.5M
$98.6M
Q1 24
$78.3M
$94.7M
Net Profit
RMAX
RMAX
TOI
TOI
Q4 25
$1.4M
$-7.5M
Q3 25
$4.0M
$-16.5M
Q2 25
$4.7M
$-17.0M
Q1 25
$-2.0M
$-19.6M
Q4 24
$5.8M
$-13.2M
Q3 24
$966.0K
$-16.1M
Q2 24
$3.7M
$-15.5M
Q1 24
$-3.4M
$-19.9M
Operating Margin
RMAX
RMAX
TOI
TOI
Q4 25
13.1%
-4.9%
Q3 25
25.0%
-5.9%
Q2 25
19.3%
-9.4%
Q1 25
7.2%
-9.5%
Q4 24
5.9%
-11.9%
Q3 24
19.4%
-13.9%
Q2 24
20.6%
-16.6%
Q1 24
5.8%
-19.0%
Net Margin
RMAX
RMAX
TOI
TOI
Q4 25
2.0%
-5.3%
Q3 25
5.4%
-12.1%
Q2 25
6.4%
-14.2%
Q1 25
-2.6%
-18.8%
Q4 24
8.0%
-13.1%
Q3 24
1.2%
-16.1%
Q2 24
4.7%
-15.7%
Q1 24
-4.3%
-21.0%
EPS (diluted)
RMAX
RMAX
TOI
TOI
Q4 25
$-0.04
Q3 25
$-0.14
Q2 25
$-0.15
Q1 25
$-0.21
Q4 24
$-0.14
Q3 24
$-0.18
Q2 24
$-0.17
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RMAX
RMAX
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$118.7M
Total DebtLower is stronger
$432.2M
Stockholders' EquityBook value
$452.4M
$-15.7M
Total Assets
$582.5M
$164.7M
Debt / EquityLower = less leverage
0.96×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RMAX
RMAX
TOI
TOI
Q4 25
$118.7M
Q3 25
$107.5M
Q2 25
$94.3M
Q1 25
$89.1M
Q4 24
$96.6M
Q3 24
$83.8M
Q2 24
$66.1M
$9.9M
Q1 24
$82.1M
$29.8M
Total Debt
RMAX
RMAX
TOI
TOI
Q4 25
$432.2M
Q3 25
$433.3M
Q2 25
$434.4M
Q1 25
$435.3M
Q4 24
$436.2M
Q3 24
$437.2M
Q2 24
$438.1M
Q1 24
$439.0M
Stockholders' Equity
RMAX
RMAX
TOI
TOI
Q4 25
$452.4M
$-15.7M
Q3 25
$448.1M
$-12.3M
Q2 25
$442.4M
$-9.0M
Q1 25
$433.5M
$5.1M
Q4 24
$429.5M
$3.6M
Q3 24
$423.1M
$15.5M
Q2 24
$418.4M
$29.2M
Q1 24
$412.0M
$41.3M
Total Assets
RMAX
RMAX
TOI
TOI
Q4 25
$582.5M
$164.7M
Q3 25
$582.2M
$163.6M
Q2 25
$574.8M
$159.8M
Q1 25
$571.4M
$164.0M
Q4 24
$581.6M
$172.7M
Q3 24
$578.6M
$179.2M
Q2 24
$571.4M
$179.6M
Q1 24
$566.7M
$204.5M
Debt / Equity
RMAX
RMAX
TOI
TOI
Q4 25
0.96×
Q3 25
0.97×
Q2 25
0.98×
Q1 25
1.00×
Q4 24
1.02×
Q3 24
1.03×
Q2 24
1.05×
Q1 24
1.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RMAX
RMAX
TOI
TOI
Operating Cash FlowLast quarter
$40.9M
$3.2M
Free Cash FlowOCF − Capex
$33.5M
$2.2M
FCF MarginFCF / Revenue
47.1%
1.5%
Capex IntensityCapex / Revenue
10.4%
0.7%
Cash ConversionOCF / Net Profit
28.39×
TTM Free Cash FlowTrailing 4 quarters
$56.8M
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RMAX
RMAX
TOI
TOI
Q4 25
$40.9M
$3.2M
Q3 25
$17.7M
$-12.6M
Q2 25
$4.6M
$-10.2M
Q1 25
$5.7M
$-5.0M
Q4 24
$59.7M
$4.2M
Q3 24
$17.6M
$819.0K
Q2 24
$15.9M
$-15.7M
Q1 24
$9.4M
$-15.9M
Free Cash Flow
RMAX
RMAX
TOI
TOI
Q4 25
$33.5M
$2.2M
Q3 25
$16.4M
$-13.2M
Q2 25
$2.9M
$-11.4M
Q1 25
$4.0M
$-5.3M
Q4 24
$53.0M
$2.4M
Q3 24
$16.3M
$417.0K
Q2 24
$14.0M
$-17.5M
Q1 24
$6.8M
$-16.5M
FCF Margin
RMAX
RMAX
TOI
TOI
Q4 25
47.1%
1.5%
Q3 25
22.4%
-9.7%
Q2 25
4.0%
-9.5%
Q1 25
5.3%
-5.1%
Q4 24
73.2%
2.4%
Q3 24
20.8%
0.4%
Q2 24
17.8%
-17.7%
Q1 24
8.6%
-17.4%
Capex Intensity
RMAX
RMAX
TOI
TOI
Q4 25
10.4%
0.7%
Q3 25
1.8%
0.4%
Q2 25
2.2%
1.0%
Q1 25
2.3%
0.3%
Q4 24
9.1%
1.8%
Q3 24
1.7%
0.4%
Q2 24
2.4%
1.9%
Q1 24
3.3%
0.6%
Cash Conversion
RMAX
RMAX
TOI
TOI
Q4 25
28.39×
Q3 25
4.45×
Q2 25
0.97×
Q1 25
Q4 24
10.28×
Q3 24
18.22×
Q2 24
4.29×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RMAX
RMAX

Franchising Segment$50.1M70%
Broker Fees$13.9M20%
Annual Dues$7.4M10%

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons